The Lucid Ultra 128 is a premium prescription behind-the-ear hearing aid priced at $5,000, placing it in the highest price tier. In our lab testing, it achieved a SoundScore of 4.21/5 and an A grade, ranking #3 among 34 prescription hearing aids tested.
This device demonstrates exceptional speech performance, scoring nearly a full point above the category average in both quiet and noisy environments. For users who prioritize conversation clarity, the Lucid Ultra 128 delivers strong results across listening conditions. Own-voice comfort also measured slightly above average, suggesting reasonable occlusion management with its closed vented dome coupling.
However, the Lucid Ultra 128 shows notable weaknesses in other areas. Music streaming quality scored 0.93 points below the category average, which may disappoint users who frequently stream audio from their phones. More significantly, feedback handling dropped substantially in the tuned fit condition, measuring over 3 points below average overall. This could limit fitting flexibility for users requiring more gain.
At this price point, the Lucid Ultra 128 faces stiff competition from devices like the Oticon Intent (4.70) and Phonak Sphere Infinio (4.64), which outperform it while costing the same. Budget-conscious buyers might consider the Widex Moment SmartRIC at $4,598, which delivers comparable overall performance. The Lucid Ultra 128 is best suited for users who prioritize speech clarity above streaming quality and who achieve good results with the initial fit settings.
